At the news
? BEARISHIMPACT 6/10 424B5 filed Aug 4, 2026 at 16:59 ET
Tyra Biosciences has amended its existing at-the-market (ATM) equity offering agreement with TD Cowen, increasing the maximum aggregate offering amount from $150 million to $250 million after fully utilizing the prior $150 million capacity. The filing signals ongoing dilution risk for existing shareholders as the company continues to access the public equity markets for capital, likely to fund its clinical-stage pipeline. With a $1.9B market cap and high short interest (~16.7%), the market may view this expanded ATM capacity as a near-term overhang on the stock.
- Tyra Biosciences has fully utilized its prior $150 million ATM facility and amended the agreement to allow up to $250 million in total common stock sales.
- The amendment was entered into on August 4, 2026, and the last reported sale price on August 3, 2026 was $32.04 per share.
- The company is a clinical-stage biopharmaceutical firm with no disclosed revenue in this filing, relying on equity offerings for capital.
- Short interest is approximately 16.7% of estimated shares outstanding as of mid-July 2026, indicating significant bearish positioning.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access